ENGENE HOLDINGS INC (ENGN)
CA29286M1059 - Common Stock
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Thursday's session: top gainers and losers
Which stocks are moving on Thursday?
Engene Holdings Becomes Oversold (ENGN)
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down.
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update
enGene to Participate in Upcoming Investor Conferences
Engene Holdings Becomes Oversold (ENGN)
enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
enGene Announces Appointment of Ron Cooper as Chief Executive Officer
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
ENGN Stock Earnings: enGene Holdings Misses EPS for Q2 2024
ENGN stock results show that enGene Holdings missed analyst estimates for earnings per share the second quarter of 2024.
ENGN Stock Earnings: enGene Holdings Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips enGene Holdings (NASDAQ:ENGN) just reported results for the second quarter of 2...
enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update
Engene Holdings Breaks Below 200-Day Moving Average - Notable for ENGN
enGene to Present at the Jefferies Global Healthcare Conference
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
Relative Strength Alert For Engene Holdings
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting
/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN) or ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in...
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting
/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN) or ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program...
Engene Holdings is Now Oversold (ENGN)
enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development
/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead...
enGene Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development
/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead...
engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development
/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product...
/C O R R E C T I O N -- enGene Inc./
In the news release, engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development, issued 09-Apr-2024 by...
enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development
/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead...
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress
/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead...
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress
/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product...
enGene To Present at the Leerink Partners Global Biopharma Conference
/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN) or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in...
enGene says Jason Hanson to resign as CEO (NASDAQ:ENGN)
enGene Holdings Inc. (Nasdaq: ENGN) announces CEO resignation due to personal reasons, initiates search for successor.
enGene Announces Oversubscribed $200 Million Private Placement Financing
/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70...
enGene Announces Oversubscribed $200 Million Private Placement Financing
/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a...
enGene Announces Leadership Succession Plan
/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN) ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70...
enGene Announces Leadership Succession Plan
/CNW/ - enGene Holdings Inc. (Nasdaq: ENGN) ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a...
enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary
/CNW/ - enGene Holdings Inc. ("enGene," (Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for...
enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary
/PRNewswire/ - enGene Holdings Inc. ("enGene," (Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for...